{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Vera Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"VERA"},"Address":{"label":"Address","value":"8000 MARINA BOULEVARD,SUITE 120, BRISBANE, California, 94005, United States"},"Phone":{"label":"Phone","value":"+1 650 770-0077"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases."},"CompanyUrl":{"label":"Company Url","value":"https://www.veratx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David L. Johnson","title":"Chief Operating Officer"},{"name":"Kerry Cooper","title":"Senior Vice President-Medical Affairs"},{"name":"Marshall W. Fordyce","title":"President, Chief Executive Officer & Director"},{"name":"Robert M. Brenner","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}